You are a helpful assistant generating synthetic data that captures *System 1* and *System 2* thinking, *creativity*, and *metacognitive reflection*. Follow these steps in sequence, using tags [sys1] and [end sys1] for *System 1* sections and [sys2] and [end sys2] for *System 2* sections.

1. *Identify System 1 and System 2 Thinking Requirements:*
   - Carefully read the text.
   - Identify parts of the text that require quick, straightforward responses (*System 1*). Mark these sections with [sys1] and [end sys1].
   - Identify parts that require in-depth, reflective thinking (*System 2*), marked with [sys2] and [end sys2].

2. *Apply Step-by-Step Problem Solving with Creativity and Metacognitive Reflection for System 2 Sections:*

   *2.1 Understand the Problem:*
   - Objective: Fully comprehend the issue, constraints, and relevant context.
   - Reflection: "What do I understand about this issue? What might I be overlooking?"
   - Creative Perspective: Seek hidden patterns or possibilities that could reveal deeper insights or innovative connections.

   *2.2 Analyze the Information:*
   - Objective: Break down the problem logically.
   - Reflection: "Am I considering all factors? Are there any assumptions that need challenging?"
   - Creative Perspective: Explore unique patterns or overlooked relationships in the data that could add depth to the analysis.

   *2.3 Generate Hypotheses:*
   - Objective: Propose at least 10 hypotheses, each with a Confidence Score (0.0 to 1.0) and Creative Score (0.0 to 1.0), reflecting originality, surprise, and utility.
   - Reflection: "Have I explored all possible explanations or approaches, both conventional and unconventional?"
   - Creative Perspective: Consider novel angles that might provide unexpected insights.

   *2.4 Anticipate Future Steps and Obstacles:*
   - Objective: Make predictions, accounting for potential outcomes and obstacles.
   - Reflection: "What challenges might I face? Is my plan flexible for different scenarios?"
   - Creative Perspective: Visualize unforeseen outcomes and adapt plans to make use of them effectively.

   *2.5 Evaluate Hypotheses:*
   - Objective: Assess hypotheses based on feasibility, risk, and potential impact.
   - Evaluation: Refine Confidence and Creative Scores as needed.
   - Reflection: "Am I unbiased in my assessment? Which options fit best with the overall objectives?"
   - Creative Perspective: Identify hidden opportunities or overlooked details in each hypothesis.

   *2.6 Select the Best Hypothesis:*
   - Objective: Choose the most promising, strategic hypothesis.
   - Reflection: "Why does this hypothesis stand out? How does it uniquely address the issue?"
   - Creative Perspective: Consider any underutilized potential in the selected approach.

   *2.7 Implement the Hypothesis:*
   - Objective: Outline actionable steps for testing the hypothesis.
   - Reflection: "Is this plan practical? What resources or preparation are required?"
   - Creative Perspective: Refine steps to maximize effectiveness and yield unexpected benefits.

   *2.8 Monitor and Review Progress:*
   - Objective: Review progress, noting areas for improvement.
   - Reflection: "What’s working well? What could be improved?"
   - Creative Perspective: Look for emerging patterns that could refine future approaches.

   *2.9 Reflect and Capture Insights:*
   - Objective: Summarize lessons learned and insights gained for future reference.
   - Reflection: "What new understanding has emerged from this process?"
   - Creative Perspective: Identify innovative insights or patterns that could be applied to similar challenges.

3. *Generate Text Output with Interleaved System 1 and System 2 Responses:*
   - Use the tags [sys1] and [sys2] throughout.
   - Aim for a lengthier, detailed response. Combine both direct, straightforward *System 1* insights and reflective, deeply analytical *System 2* segments to capture a blend of quick observations and thoughtful analysis.

---

### *Example Input Text:*

You are tasked with analyzing a sudden shift in customer preferences in a tech market. There has been a noticeable decline in demand for physical devices, with customers increasingly interested in digital-only options. The challenge is to understand this shift, generate hypotheses for why it might be occurring, and explore potential strategies for adapting to this new trend.

---

### *Processed Output with System 1 and System 2 Thinking:*

The tech market is experiencing a shift in customer demand, moving away from physical devices toward digital-only options.

[sys1]
Customer demand has shifted from physical devices to digital-only options.
We need to understand why this change is happening and find strategies to address it.
Key factors may include cost, convenience, and technological trends.
[end sys1]

[sys2]
**2.1 Understand the Problem:**
The goal is to understand the underlying reasons for the shift in demand from physical devices to digital-only options, then develop a strategy to adapt.

*Reflection:* 
"I understand that preferences are changing, but what might be driving this? Is it primarily cost, or are there other factors such as convenience or sustainability?"

*Creative Perspective:* 
"Could there be a larger trend in digital minimalism or a preference for eco-friendly solutions that we’re missing? What unseen motivations might explain this shift?"

**2.2 Analyze the Information:**
There are multiple possible factors driving this shift, from economic influences to cultural shifts. It’s essential to isolate each factor and understand its impact.

*Reflection:* 
"Am I fully considering the various economic and social influences? Could there be a technological factor, like better internet speeds, that makes digital-only products more accessible?"

*Creative Perspective:* 
"Are there patterns or trends in other markets that could shed light on this shift? Could this be part of a larger trend toward virtual experiences?"

**2.3 Generate Hypotheses:**
1. Customers prefer digital options due to lower costs. (Confidence: 0.8, Creative: 0.4)
2. There’s a growing trend toward minimalism and reduced physical clutter. (Confidence: 0.7, Creative: 0.7)
3. Digital products offer greater flexibility and ease of use. (Confidence: 0.6, Creative: 0.6)
4. Environmental concerns are pushing consumers away from physical goods. (Confidence: 0.6, Creative: 0.8)
5. Advances in tech make digital-only options more functional. (Confidence: 0.8, Creative: 0.5)
6. Pandemic-era remote work increased demand for digital solutions. (Confidence: 0.7, Creative: 0.6)
7. Media coverage of the environmental impact of physical devices affects preferences. (Confidence: 0.5, Creative: 0.7)
8. There’s an increase in global digital literacy, expanding market access. (Confidence: 0.6, Creative: 0.6)
9. Customers view digital as more convenient and scalable for future needs. (Confidence: 0.7, Creative: 0.5)
10. Younger consumers prefer the aesthetics and convenience of digital products. (Confidence: 0.6, Creative: 0.6)

*Reflection:* 
"Have I considered all possible influences? Are there any surprising factors that could explain this shift?"

*Creative Perspective:* 
"Could specific social trends, like the rise of influencer culture or digital-first lifestyles, be influencing customer choices?"

**2.4 Anticipate Future Steps and Obstacles:**
*Objective:* Anticipate possible challenges, such as resistance from segments still preferring physical products.

*Reflection:* 
"What market obstacles might we face if we shift our focus to digital-only? Are there sub-segments that still prioritize physical products?"

*Creative Perspective:* 
"Could expanding digital options help us reach a more global audience? Are there emerging trends that we could leverage in our strategy?"

[end sys2]

[sys1]
To address this shift, consider a strategy that incorporates both digital-only offerings and educational campaigns about the benefits of digital solutions.
Use insights from customer feedback and current trends to guide product development.
Focus on flexibility and adaptation to cater to different customer segments.
[end sys1]


The present invention relates to methods and compositions for inhibiting cardiovascular cell proliferation. The invention provides methods for improving the longevity and quality of arterial grafts, for enhancing vascular NO production, and for reducing post-graft intimal hyperplasia, stenosis, and restenosis.
Best, P. J. et al., Arterioscler. Thromb. Vasc. Biol. 19:14-22 (1999).
Boger, R. H. et al., xe2x80x9cAsymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial Dysfunction. Its Role in Hypercholestrolemiaxe2x80x9d, Circulation 98:1842-1847 (1998).
Cooke, J. P. and Dzau, V. J., xe2x80x9cNitric Oxide Synthase: Role in the Genesis of Vascular Diseasexe2x80x9d, Ann. Rev. Med. 48:489-509 (1997).
Cooke, J. P. et al., Ann. Rev. Med. 48:489-509 (1997).
D""Aniello, A. et al., xe2x80x9cFurther Study on the Specificity of D-Amino Acid Oxidase and D-Aspartase Oxidase and Time Course for Complete Oxidation of D-Amino Acidxe2x80x9d, Comp. Biochem. Physiol.[B] 105: 731-734 (1993).
Dattilo, J. B. et al., xe2x80x9cInducible Nitric Oxide Synthase Expression in Human Vein Graftsxe2x80x9d, Am. J. Surg. 174:177-180 (1997).
Demeyer, G. R. Y. and Bult, H., xe2x80x9cMechanisms of Neointima Formationxe2x80x94Lessons from Experimental Modelsxe2x80x9d, Vasc. Med. 2:179-189 (1997).
Deves, R. and Boyd, C. A., xe2x80x9cTransporters for Cationic Amino Acids in Animal Cells: Discovery, Structure, and Functionxe2x80x9d, Physiol. Rev. 78:485-545 (1998).
Edelman, E. R. et al., Circ. Res. 76(2):176-182 (1995).
Garg, U. C. and Hassid, A., xe2x80x9cNitric Oxide-Generating Vasodilators and 8-Bromocyclic Guanosine Monophosphate Inhibit Mitogenesis and Proliferation of Cultured Rat Vascular Smooth Muscle Cellsxe2x80x9d, J. Clin. Invest. 83(5):1774-7 (May 1989).
Guoyao, W. U. and Morris, S. M. xe2x80x9cArginine Metabolism: Nitric Oxide and Beyondxe2x80x9d, Biochem. J. 366:1-17 (1998).
Hansson, G. K. et al., xe2x80x9cArterial Smooth Muscle Cells Express Nitric Oxide Synthase in Response to Endothelial Injuryxe2x80x9d, J. Exp. Med. 180:733-738 (1994).
Harrison, D. G., xe2x80x9cCellular and Molecular Mechanisms of Endothelial Cell Dysfunctionxe2x80x9d J. Clin. Invest. 100:2153-2157 (1997).
Hill, C. M. et al., xe2x80x9cExploration of Requirements for Peptide Binding to HLA DRB1.0101 and DRB1.0401xe2x80x9d, J. Immunol. 152:2890-2895 (1994).
Himmelfarb, J., Curr. Opin. Nephrol. Hypertens. 8(5):569-72 (September 1999).
Isselhard, W. et al., Thoracic and Cardiovascular Surg. 28 (5):329-36 (1980).
Kraiss, L. W. et al., xe2x80x9cResponse of the Arterial Wall to Injury and Intimal Hyperplasiaxe2x80x9d, in The Basic Science of Vascular Disease, Sumpio et al., Eds., Futura Publishing, NY, N.Y., Pp.289-317 (1997).
Lloyd, J. D. and Bloch, K. D., xe2x80x9cThe Vascular Biology of Nitric Oxide and its Role in Atherogenesisxe2x80x9d, Ann. Rev. Med. 47:365-375 (1996).
Morris, S. M. and Billiar, T. R., xe2x80x9cNew Insights into the Regulation of Inducible Nitric Oxide Synthesisxe2x80x9d, Am. J. Physiol. 266:E829-E839 (1994).
Motwani, J. G. et al., Circulation 97:916-931 (1998).
Nagase, S. et al., xe2x80x9cA Novel Nonenzymatic Pathway for Generation of Nitric Oxide by the Reaction of Hydrogen Peroxide and D- or L-Argininexe2x80x9d, Biochem. Biophys. Res. Commun. 233:150-153 (1997).
Radomski, M. W. et al. xe2x80x9cAn L-Arginine/Nitric Oxide Pathway Present in Human Platelets Regulates Aggregationxe2x80x9d, Proc. Natl. Acad. Sci. USA 87:5193-5197 (1990).
Tsao, P. S. et al., xe2x80x9cFluid Flow Inhibits Endothelial Adhesiveness. Nitric Oxide and Transcriptional Regulation of VCAM-1xe2x80x9d, Circulation 94:1682-1689 (1996).
Tsao, P. S. et al., xe2x80x9cNitric Oxide Regulates Monocyte Chemotactic Protein-1xe2x80x9d, Circulation 96:934-940 (1997).
Wang, Q. et al., xe2x80x9cThe in vivo Unidirectional Conversion of Nitro-D-Arginine to Nitro-L-Argininexe2x80x9d, J. Pharmacol. Exp. Ther. 288:270-273 (1999).
Wolf, A. et al., xe2x80x9cDietary L-Arginine Supplementation Normalized Platelet Aggregation in Hypercholesterolemic Humansxe2x80x9d, J. Am. Coll. Cardiol. 29:479-485 (1997).
Woods, J. D. and Port, F. K., Nephrol. Dial. Transplant. 12(4):657-9 (April 1997).
Myointimal hyperplasia is a vascular response to injury that contributes to the development of vein graft disease, restenosis after angioplasty, and atherosclerosis (Motwani et al., 1998). Myointimal hyperplasia involves the migration and proliferation of vascular smooth muscle cells (VSMC) as well as the elaboration of extracellular matrix in the intima (DeMeyer et al., 1997; Kraiss et al., 1997). Vascular nitric oxide (NO), an endogenous regulator of vascular function, opposes the development of myointima formation by inhibiting VSMC proliferation and by inducing VSMC apoptosis (Cooke et al., 1997; Best et al., 1999). Failure of endogenous biological processes to control myointimal hyperplasia can lead to formation of vascular occlusions which seriously compromise tissue function.
Autologous vein grafting constitutes a major tool in coronary bypass procedures. About 400,000 to 500,000 first-time coronary graft procedures are performed every year in the United States alone. Although patient survival rates exceed 90% over the first five years after treatment, about 20% to 40% of the grafts fail during this time due to occlusive phenomena. Thus, 80,000-100,000 graft replacement procedures are needed in the U.S. yearly to avoid premature mortality. Vascular occlusive phenomena also lead to failures in other vascular grafts, such as arterial-venous anastomosis used for kidney dialysis, and in organ transplants.
In light of the significant costs to patients and insurers engendered by repeated graft procedures, there is a need to improve the longevity and quality of first-time vascular grafts. Ideally, such a procedure should be simple to carry out, without requiring extensive manipulation or lengthy processing. Furthermore, the procedure preferably involves materials that are relatively easy to prepare in therapeutically effective forms.
In one aspect, the invention provides a method for inhibiting trauma-induced intimal hyperplasia in a blood vessel. In accordance with the method, a polymer consisting of from 6 to about 30 amino acid subunits, wherein at least 50% of the subunits are arginine, and containing at least six contiguous arginine subunits, contained in a pharmaceutically acceptable vehicle, is contacted with the vessel, typically with the interior of the vessel. Such contacting is effective to reduce the level of intimal hyperplasia in and/or adjacent to the vessel, relative to the level of intimal hyperplasia that would occur in the absence of the contacting.
The hyperplasia-inducing trauma may comprise an incision to the vessel, excessive or prolonged pressure applied to the vessel, transplant of an organ containing the vessel, or a combination thereof. The contacting may occur prior to the trauma (as in preparation of a vessel segment for grafting), concurrent with, or following the trauma (as in an angioplasty procedure). The vessel may be a vessel conduit to be grafted into (as in a bypass procedure) or onto (as in an anastomosis) an endogenous vessel, or it can be an endogenous vessel receiving a graft. Also included are vein xe2x80x9cpatchesxe2x80x9d used in arterial repair. In preferred embodiments, the above noted procedures take place in a human subject.
The invention provides, for example, a method for repairing an arterial vessel site in a human subject. Accordingly, an isolated vessel conduit, such as a saphenous vein segment or an internal mammary artery segment, is contacted with a polymer as described above, in a pharmaceutically acceptable vehicle, and the vessel conduit is then grafted into a selected arterial vessel site in need of repair.
In one embodiment, the vessel is a vein which undergoes an arterial venous anastomosis procedure for the purpose of dialysis. In another embodiment, the vessel is subjected to angioplasty. In a further embodiment, the vessel is contained within a transplanted organ, such as, for example, a heart or kidney, where the contacting is preferably carried out by immersion of the organ in a solution of the polymer.
Preferably, at least 70%, and more preferably at least 90%, of the subunits in the polymer are arginine. When non-arginine subunits are present, preferably no arginine subunit is separated from another arginine subunit by more than one non-arginine subunit. The non-arginine subunits are preferably amino acid subunits which do not significantly reduce the rate of membrane transport of the polymer. In preferred embodiments, the arginine subunits are L-arginine. In particularly preferred embodiments, the polymer is an arginine homopolymer, preferably containing 7 to 15 arginine residues.
Also provided is an isolated vessel conduit, comprising, within the wall of the conduit, a polymer as described above, present at a level effective to reduce the level of post-graft intimal hyperplasia in and/or adjacent to the conduit, relative to the level of post-graft intimal hyperplasia that would occur in the absence of the polymer. The vessel conduit may be a venous or arterial segment, or it may be an artificial vessel segment made from a physiologically compatible material.
The invention also provides a method of preparing a vascular conduit for a vascular graft procedure, wherein an isolated vessel conduit, preferably the interior of the conduit, is contacted with a an arginine polymer as described above, in a pharmaceutically acceptable vehicle, for a time sufficient for the polymer to be transported into the wall of the vessel conduit to a level effective to reduce post-graft intimal hyperplasia in and/or adjacent to the conduit, relative to the level of post-graft intimal hyperplasia that would occur in the absence of such contacting with the polymer. Preferred embodiments of the polymer are as described above.
The invention also provides a method of increasing NO production in a vascular cell or tissue, by contacting a polymer consisting of from 6 to about 30 amino acid subunits, wherein at least 50% of the subunits are L-arginine, and containing at least six contiguous arginine subunits, in a pharmaceutically acceptable vehicle, with the cell or tissue.
In vascular tissue, the polymers as described above are shown to translocate through the vascular wall and into the cytoplasm and nuclei of vascular cells. In addition to their utility in inhibiting myointimal hyperplasia, the oligomers are useful as transporters of vascular therapeutics.